A pilot RCT finds a culturally tailored WeChat-delivered programme improves self-efficacy and reduces diabetes distress in Chinese Americans with type 2 diabetes. PICO summary and commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A small crossover trial finds a mulberry leaf and corn silk functional milk lowers postprandial glucose only in an overweight prediabetic subgroup. PICO summary and expert commentary.
The Look AHEAD trial demonstrated that intensive lifestyle intervention targeting weight loss in overweight or obese adults with type 2 diabetes did not reduce cardiovascular events over 9.6 years despite clear differences in weight, fitness, and glycaemic control, establishing a critical negative result that informed the rationale for pharmacological obesity treatment with greater weight loss efficacy.
The REWIND trial demonstrated that dulaglutide reduces 3-point MACE in a broad type 2 diabetes population of which 69% had no established cardiovascular disease, with a significant 24% reduction in nonfatal stroke and consistent renal benefit, extending GLP-1 receptor agonist cardiovascular protection into a primary prevention context.
The SUSTAIN-6 trial demonstrated that once-weekly semaglutide reduced 3-point MACE by 26% in high-cardiovascular-risk type 2 diabetes, driven primarily by a significant 39% reduction in nonfatal stroke, while identifying a retinopathy complication signal attributable to rapid glucose lowering in patients with pre-existing retinopathy.
The LEADER trial demonstrated that liraglutide significantly reduced 3-point MACE and cardiovascular mortality in patients with type 2 diabetes and high cardiovascular risk, becoming the first GLP-1 receptor agonist CVOT to demonstrate superiority and characterising an atherosclerotic rather than heart failure protection profile distinct from SGLT2 inhibitors.
DAPA-CKD demonstrated that dapagliflozin reduced the composite of a sustained 50% or greater eGFR decline, end-stage kidney disease, or renal or cardiovascular death by 39% in patients with albuminuric CKD with or without type 2 diabetes, extending nephroprotective SGLT2 inhibition beyond diabetic nephropathy to a broad CKD population for the first time.
A four-arm RCT finds combining training with a polyphenol supplement improves prediabetes markers most, with exercise the main driver. PICO summary and expert commentary.
An RCT finds the AntiAGE-Biom probiotic does not lower HbA1c but shows a subgroup body-composition signal in type 2 diabetes. PICO summary and expert commentary.
An RCT finds Chester Step Test-guided post-dinner exercise lowers postprandial glucose and variability in type 2 diabetes on exercise days. PICO summary and expert commentary.